RE: Bravo Vlad27 Nov 2025 13:10
The broadly understood definition of clinical proof of concept is as follow:-
“Proof of concept (POC) may be defined as the earliest point in the drug development process at which the weight of evidence suggests that it is "reasonably likely" that the key attributes for success are present and the key causes of failure are absent. POC is multidimensional but is focused on attributes that, if not addressed, represent a threat to the success of the project in crucial areas such as safety, efficacy, pharmaceutics, and commercial and regulatory issues.”
From the Prospectus
"Three patients have been treated with HG-CT-1 in the ongoing Phase I clinical trial, with encouraging safety data and early indications of efficacy. However, there can be no assurance that treatment with HG-CT-1 will continue to demonstrate safety and efficacy as the trial progresses. "
"The Company’s near- and medium-term goal is to advance several product candidates into clinical trials to achieve clinical proof of concept. This includes validation of their safety and potential efficacy in patients."
I'd suggest we're at the point of proof of concept in line with the above definition. I agree, we need the money to realise true value. To reach the inflection point of all inflection points. Indeed, the prospectus references this very pont:-
"Successful execution of this plan requires a significant capital injection, which is likely to bring the Group to an inflection point of having clinically validated product candidates that will likely save lives and will likely enable the Group to achieve maximum shareholder value. "
So, at this stage, to be trying to but the worries up people about raising cash when it would seem to be the final piece of the jigsaw seems rather misguided or indeed, intentionally misleading.
Sign In
Follow the stocks
